VolitionRx (VNRX) Competitors

Lifecore Biomedical (NASDAQ:LFCR) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Do institutionals and insiders hold more shares of LFCR or VNRX?

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 32.2% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 10.4% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media favor LFCR or VNRX?

In the previous week, VolitionRx had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 6 mentions for VolitionRx and 5 mentions for Lifecore Biomedical. VolitionRx's average media sentiment score of 0.77 beat Lifecore Biomedical's score of 0.10 indicating that VolitionRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VolitionRx	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend LFCR or VNRX?

Lifecore Biomedical presently has a consensus target price of $8.00, suggesting a potential upside of 7.82%. VolitionRx has a consensus target price of $3.50, suggesting a potential upside of 443.65%. Given VolitionRx's stronger consensus rating and higher probable upside, analysts plainly believe VolitionRx is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
VolitionRx	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk & volatility, LFCR or VNRX?

Lifecore Biomedical has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Which has higher earnings and valuation, LFCR or VNRX?

VolitionRx has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	2.15	-$38.72M	-$1.31	-5.66
VolitionRx	$1.31M	51.17	-$35.32M	-$0.27	-2.38

Is LFCR or VNRX more profitable?

Lifecore Biomedical has a net margin of -31.70% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-31.70%	-846.51%	-13.03%
VolitionRx	-2,321.14%	N/A	-163.39%

Summary

VolitionRx beats Lifecore Biomedical on 11 of the 16 factors compared between the two stocks.